June 2023
Volume 64, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2023
Ocular surface platelet-rich plasma membranes: setting preparation conditions
Author Affiliations & Notes
  • Alberto Castilo
    Ophtalmology, Instituto Tecnologico y de Estudios Superiores de Monterrey, Monterrey, Nuevo Leon, Mexico
  • Judith Zavala
    Ophtalmology, Instituto Tecnologico y de Estudios Superiores de Monterrey, Monterrey, Nuevo Leon, Mexico
  • Katiana Flores Nucamendi
    Ophtalmology, Instituto Tecnologico y de Estudios Superiores de Monterrey, Monterrey, Nuevo Leon, Mexico
  • David Rodriguez
    Ophtalmology, Instituto Tecnologico y de Estudios Superiores de Monterrey, Monterrey, Nuevo Leon, Mexico
  • Alfredo Del Castillo
    Ophtalmology, Instituto Tecnologico y de Estudios Superiores de Monterrey, Monterrey, Nuevo Leon, Mexico
  • Jorge E Valdez
    Ophtalmology, Instituto Tecnologico y de Estudios Superiores de Monterrey, Monterrey, Nuevo Leon, Mexico
  • Footnotes
    Commercial Relationships   Alberto Castilo None; Judith Zavala None; Katiana Flores Nucamendi None; David Rodriguez None; Alfredo Del Castillo None; Jorge Valdez None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2023, Vol.64, 5167. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Alberto Castilo, Judith Zavala, Katiana Flores Nucamendi, David Rodriguez, Alfredo Del Castillo, Jorge E Valdez; Ocular surface platelet-rich plasma membranes: setting preparation conditions. Invest. Ophthalmol. Vis. Sci. 2023;64(8):5167.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Platelet-rich plasma (PRP) membranes have high potential for use as therapeutic agents in ocular surface disorders. The reported methods vary on centrifugation and PRP separation, which can impact the growth factors concentrations and cellularity, affecting their functionality. We evaluated the impact of the variation in the centrifugation speed on the cellularity and concentration of growth factors of PRP membranes for ophthalmic use.

Methods : This study was conducted according to the ARVO guidelines for Human research (Ethics Committee 018-2022-CI-R, 2022). PRP was obtained from 16 healthy subjects. The concentrations of vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF) and transforming growth factor beta 1 (TGF-B1) were evaluated by enzyme-linked immunosorbent assays (ELISA) in PRP obtained with 3 centrifugation speeds: 580 g, 1000 g, and 2000 g (8 minutes at 25 degrees Celsius). Cellularity was assessed by H&E and Masson’s trichrome staining, measured as moderate or abundant, and analyzed by chi-squared test. ANOVA were performed to evaluate the significant difference between the concentrations of growth factors and the centrifugation speed.

Results : The highest VEGF concentration was 482 pg/ml (SE: 98.65) obtained at 2000 g. The PDGF highest concentration was observed at 1597.75 pg/ml (SE: 60.85) obtained at 580 g. TGF-B1 highest concentration was 843.05 pg/ml (SE: 90.70) obtained at 1000 g. There was no significant difference between the centrifugation speeds and concentration of VEGF, PDGF and TGF-B1 (p>0.05). The observed cellularity had a moderate predominance for the 580 g and 2000 g techniques, while abundant cellularity was observed in the 1000 g technique. No significant difference was found between the evaluated techniques (p=0.16). In the evaluation using Masson's trichrome, precipitates highly suggestive of fibrin were observed abundantly in the 1000 g technique but there was no significant difference between the techniques (p=0.07).

Conclusions : This study demonstrated that the speed of centrifugation does not impact on the growth factors concentration and cellularity of the PRP. Further studies should be carried out to evaluate the impact of the separation technique to obtain PRP to produce membranes for ophthalmic use.

This abstract was presented at the 2023 ARVO Annual Meeting, held in New Orleans, LA, April 23-27, 2023.

 

Figure 1. Obtention of platelet rich plasma (PRP) membranes and growth factor concentrations

Figure 1. Obtention of platelet rich plasma (PRP) membranes and growth factor concentrations

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×